Lakefront Biotherapeutics NV (XTER:GXE) Total Receivables: €54 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XTER:GXE Lakefront Biotherapeutics NV XTER:GXE
51 GF Score
Price €25.72
GF Value €109.30
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Lakefront Biotherapeutics NV Total Receivables?

Lakefront Biotherapeutics NV XTER:GXE -0.92% 51 Total Receivables is €54 Mil as of Mar. 2026. GuruFocus rates XTER:GXE with a GF Score™ of 51/100 and a GF Value™ of €109.30 (Possible Value Trap). The stock has 4 warning signs investors should review.

Lakefront Biotherapeutics NV's Total Receivables for the quarter that ended in Mar. 2026 was €54 Mil.

Lakefront Biotherapeutics NV Total Receivables Related Terms

Lakefront Biotherapeutics NV Total Receivables Historical Data

* Premium members only.

The historical data trend for Lakefront Biotherapeutics NV's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lakefront Biotherapeutics NV Total Receivables Chart

Lakefront Biotherapeutics NV Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 128.60 77.34 65.66 88.09 53.20

Lakefront Biotherapeutics NV Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 83.49 87.84 77.67 53.20 54.03
XTER:GXE
51GF Score
Lakefront Biotherapeutics NV XTER:GXE
Total Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lakefront Biotherapeutics NV Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of €54 Mil mean?
Lakefront Biotherapeutics NV (XTER:GXE) has a Total Receivables of €54 Mil as of Mar. 2026. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Lakefront Biotherapeutics NV and its competitors.
Is Lakefront Biotherapeutics NV's Total Receivables too high?
Lakefront Biotherapeutics NV's current Total Receivables is €54 Mil. Overall, Lakefront Biotherapeutics NV has a GF Score™ of 51/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Lakefront Biotherapeutics NV's Total Receivables compare to VRTX and REGN?
Lakefront Biotherapeutics NV's Total Receivables of €54 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Biotechnology company?
A good Total Receivables depends on the Biotechnology industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Lakefront Biotherapeutics NV and its competitors. Lakefront Biotherapeutics NV's current Total Receivables is €54 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lakefront Biotherapeutics NV stock overvalued right now?
Based on GuruFocus' analysis, Lakefront Biotherapeutics NV (XTER:GXE) is currently considered Possible Value Trap. The stock's GF Value™ is €109.30, compared to a current price of €25.72 — trading 76.5% below its estimated fair value. The current Total Receivables is €54 Mil. Lakefront Biotherapeutics NV's overall GF Score™ is 51/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Lakefront Biotherapeutics NV (XTER:GXE), the current Total Receivables is €54 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lakefront Biotherapeutics NV (XTER:GXE) Overvalued in 2026?

Based on GuruFocus' analysis, Lakefront Biotherapeutics NV stock appears to be undervalued. The current stock price of €25.72 is trading 76.5% below its estimated GF Value™ of €109.30. GuruFocus considers Lakefront Biotherapeutics NV to be Possible Value Trap.

Key valuation signals for XTER:GXE:

  • Total Receivables: €54 Mil
  • GF Value™: €109.30 vs. price of €25.72 (76.5% below fair value)
  • GF Score™: 51/100 with 4 warning signs

No single metric tells the full story. See the XTER:GXE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lakefront Biotherapeutics NV Business Description

Address Schalienhoevedreef 20 T, Mechelen, BEL, 2800
Lakefront Biotherapeutics NV a biopharmaceutical company committed to improving the lives of people with severe diseases. It focuses on delivering medicines with transformational impact for patients by accelerating life-changing science and innovation in areas of high unmet need. Its pipelines includes GLPG3667, GLPG5101, and GLPG5301.
51GF Score

Get the complete analysis for XTER:GXE

Total Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€25.72
Price
€109.30
GF Value